Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cryo-Cell InternationalFRA:ZCY -2.08%63 Net Current Asset Value is €-7.13 as of May. 2026. GuruFocus rates FRA:ZCY with a GF Score™ of 63/100 and a GF Value™ of €4.69 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 271 Healthcare Providers & Services companies, Cryo-Cell International ranks worse than 369003.32% on this metric.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
Cryo-Cell International's net current asset value per share for the quarter that ended in May. 2026 was €-7.13.
The historical rank and industry rank for Cryo-Cell International's Net Current Asset Value or its related term are showing as below:
FRA:ZCY's Price-to-Net-Current-Asset-Value is not ranked *
in the Healthcare Providers & Services industry.
Industry Median: 5.87 * Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
Cryo-Cell International (FRA:ZCY) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
Cryo-Cell International Net Current Asset Value Related Terms
Cryo-Cell International Net Current Asset Value Historical Data
* Premium members only.
The historical data trend for Cryo-Cell International's Net Current Asset Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cryo-Cell International Net Current Asset Value Chart
FRA:ZCY vs CCM, CDIX, EHSI: Net Current Asset Value Comparison
For the Medical Care Facilities subindustry, Cryo-Cell International's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cryo-Cell International Price-to-Net-Current-Asset-Value vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Cryo-Cell International's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where Cryo-Cell International's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of €-7.13 mean?
Cryo-Cell International (FRA:ZCY) has a Net Current Asset Value of €-7.13 as of May. 2026. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Cryo-Cell International and its competitors. According to the industry distribution chart, Cryo-Cell International ranks #999999 out of 271 companies in the Healthcare Providers & Services industry.
Is Cryo-Cell International's Net Current Asset Value too high?
Cryo-Cell International's current Net Current Asset Value is €-7.13. Based on the distribution chart, Cryo-Cell International ranks #999999 out of 271 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Cryo-Cell International has a GF Score™ of 63/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cryo-Cell International's Net Current Asset Value compare to CCM and CDIX?
According to the Healthcare Providers & Services industry distribution chart, Cryo-Cell International ranks #999999 out of 271 companies for Net Current Asset Value. This places Cryo-Cell International in the lower half of its industry. The industry median Net Current Asset Value is 5.87. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Healthcare Providers & Services company?
The median Net Current Asset Value among Healthcare Providers & Services companies is 5.87, based on 271 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Cryo-Cell International and its competitors. For the Healthcare Providers & Services industry, the median Net Current Asset Value is 5.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cryo-Cell International's current Net Current Asset Value is €-7.13. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cryo-Cell International stock overvalued right now?
Based on GuruFocus' analysis, Cryo-Cell International (FRA:ZCY) is currently considered Possible Value Trap. The stock's GF Value™ is €4.69, compared to a current price of €2.82 — trading 39.9% below its estimated fair value. The current Net Current Asset Value is €-7.13. Cryo-Cell International's overall GF Score™ is 63/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For Cryo-Cell International (FRA:ZCY), the current Net Current Asset Value is €-7.13 as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cryo-Cell International (FRA:ZCY) Overvalued in 2026?
Based on GuruFocus' analysis, Cryo-Cell International stock appears to be undervalued.
The current stock price of €2.82 is trading 39.9% below its estimated GF Value™ of €4.69.
GuruFocus considers Cryo-Cell International to be Possible Value Trap.
Key valuation signals for FRA:ZCY:
Net Current Asset Value: €-7.13
GF Value™: €4.69 vs. price of €2.82 (39.9% below fair value)
No single metric tells the full story. See the FRA:ZCY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.
63GF Score
Get the complete analysis for FRA:ZCY
Net Current Asset Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:ZCY has been successfully added to your 
